Supernus Pharmaceuticals (NASDAQ:SUPN) Rating Increased to Strong-Buy at StockNews.com

StockNews.com upgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from a buy rating to a strong-buy rating in a report published on Sunday morning.

Separately, Cantor Fitzgerald reaffirmed a “neutral” rating and set a $36.00 price target on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th.

Supernus Pharmaceuticals Stock Performance

Shares of SUPN stock opened at $31.26 on Friday. Supernus Pharmaceuticals has a one year low of $25.53 and a one year high of $40.28. The company’s 50-day simple moving average is $36.22 and its 200-day simple moving average is $35.17. The stock has a market capitalization of $1.74 billion, a price-to-earnings ratio of 29.22 and a beta of 0.83.

Insiders Place Their Bets

In other Supernus Pharmaceuticals news, SVP Jonathan Rubin sold 927 shares of the firm’s stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $39.15, for a total value of $36,292.05. Following the transaction, the senior vice president now owns 7,853 shares of the company’s stock, valued at $307,444.95. This trade represents a 10.56 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Padmanabh P. Bhatt sold 9,477 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $39.70, for a total value of $376,236.90. Following the sale, the vice president now directly owns 10,149 shares in the company, valued at approximately $402,915.30. This trade represents a 48.29 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 11,104 shares of company stock valued at $440,263 over the last quarter. Insiders own 9.30% of the company’s stock.

Institutional Investors Weigh In On Supernus Pharmaceuticals

A number of hedge funds have recently made changes to their positions in SUPN. Pacer Advisors Inc. raised its holdings in shares of Supernus Pharmaceuticals by 29.9% during the third quarter. Pacer Advisors Inc. now owns 1,752,882 shares of the specialty pharmaceutical company’s stock valued at $54,655,000 after buying an additional 403,028 shares during the last quarter. Woodline Partners LP raised its holdings in shares of Supernus Pharmaceuticals by 124.8% during the fourth quarter. Woodline Partners LP now owns 423,828 shares of the specialty pharmaceutical company’s stock valued at $15,326,000 after buying an additional 235,257 shares during the last quarter. BNP Paribas Financial Markets raised its holdings in shares of Supernus Pharmaceuticals by 248.0% during the fourth quarter. BNP Paribas Financial Markets now owns 292,629 shares of the specialty pharmaceutical company’s stock valued at $10,581,000 after buying an additional 208,552 shares during the last quarter. Raymond James Financial Inc. acquired a new position in shares of Supernus Pharmaceuticals during the fourth quarter valued at approximately $6,847,000. Finally, Great Lakes Advisors LLC acquired a new position in shares of Supernus Pharmaceuticals during the fourth quarter valued at approximately $6,131,000.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.